https://www.selleckchem.com/pr....oducts/acetalax-oxyp
Dear Editor, the association between menopausal hormone therapy (HT) and risk of cutaneous melanoma (CM) has received renewed attention. A number of recent studies indicate increased CM risk in HT users, especially among estrogen therapy (ET) users1,2 . However, the issue remains controversial. The recent study by Olsen et al., reported no association between HT use and CM risk in a cohort of Australian women3 . The study could not stratify HT in ET and combined estrogen-progestin therapy (EPT). We believe this st
Like
Comment
Share
